Jiangsu Chinagreen Biological Technology Co Ltd
SZSE:300970
Jiangsu Chinagreen Biological Technology Co Ltd
SZSE:300970
Price:
16 CNY
3.23%
Updated:
May 15, 2024
Balance Sheet
Balance Sheet Decomposition
Jiangsu Chinagreen Biological Technology Co Ltd
Jiangsu Chinagreen Biological Technology Co Ltd
| Current Assets | 710.5m |
| Cash & Short-Term Investments | 487.1m |
| Receivables | 21m |
| Other Current Assets | 202.4m |
| Non-Current Assets | 1.4B |
| Long-Term Investments | 481.9k |
| PP&E | 1.3B |
| Intangibles | 57.8m |
| Other Non-Current Assets | 42.1m |
| Current Liabilities | 273.5m |
| Accounts Payable | 80.4m |
| Accrued Liabilities | 20.5m |
| Short-Term Debt | 24m |
| Other Current Liabilities | 148.6m |
| Non-Current Liabilities | 249.9m |
| Long-Term Debt | 179.7m |
| Other Non-Current Liabilities | 70.2m |
Balance Sheet
Jiangsu Chinagreen Biological Technology Co Ltd
Jiangsu Chinagreen Biological Technology Co Ltd
Currency: CNY
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
23
|
33
|
36
|
57
|
67
|
130
|
192
|
271
|
432
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
271
|
432
|
|
| Cash Equivalents |
23
|
33
|
36
|
57
|
67
|
130
|
192
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
76
|
22
|
93
|
39
|
359
|
100
|
|
| Total Receivables |
19
|
11
|
16
|
31
|
15
|
9
|
16
|
39
|
15
|
|
| Accounts Receivables |
14
|
6
|
7
|
10
|
15
|
9
|
16
|
37
|
12
|
|
| Other Receivables |
5
|
5
|
9
|
21
|
0
|
0
|
0
|
2
|
2
|
|
| Inventory |
13
|
22
|
24
|
39
|
67
|
66
|
84
|
108
|
157
|
|
| Other Current Assets |
1
|
4
|
16
|
1
|
2
|
5
|
5
|
143
|
6
|
|
| Total Current Assets |
56
|
70
|
91
|
204
|
173
|
302
|
336
|
920
|
710
|
|
| PP&E Net |
159
|
210
|
214
|
483
|
683
|
662
|
755
|
876
|
1 194
|
|
| PP&E Gross |
0
|
0
|
0
|
483
|
683
|
662
|
755
|
876
|
1 194
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
126
|
180
|
247
|
321
|
401
|
486
|
|
| Intangible Assets |
5
|
5
|
5
|
38
|
47
|
52
|
53
|
52
|
51
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
9
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
26
|
31
|
37
|
3
|
6
|
2
|
21
|
28
|
25
|
|
| Total Assets |
245
N/A
|
317
+29%
|
347
+10%
|
727
+110%
|
919
+26%
|
1 018
+11%
|
1 165
+14%
|
1 877
+61%
|
1 980
+6%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
6
|
11
|
8
|
13
|
22
|
20
|
29
|
38
|
57
|
|
| Accrued Liabilities |
8
|
7
|
11
|
10
|
12
|
16
|
19
|
14
|
23
|
|
| Short-Term Debt |
61
|
67
|
60
|
9
|
83
|
29
|
40
|
51
|
14
|
|
| Current Portion of Long-Term Debt |
19
|
4
|
24
|
20
|
5
|
13
|
16
|
44
|
48
|
|
| Other Current Liabilities |
28
|
38
|
34
|
35
|
97
|
35
|
32
|
25
|
43
|
|
| Total Current Liabilities |
122
|
126
|
136
|
87
|
218
|
113
|
137
|
172
|
185
|
|
| Long-Term Debt |
34
|
49
|
20
|
0
|
43
|
124
|
133
|
213
|
228
|
|
| Minority Interest |
0
|
11
|
15
|
12
|
1
|
0
|
3
|
9
|
12
|
|
| Other Liabilities |
11
|
14
|
9
|
37
|
41
|
44
|
44
|
54
|
45
|
|
| Total Liabilities |
167
N/A
|
200
+20%
|
180
-10%
|
136
-25%
|
302
+122%
|
281
-7%
|
317
+13%
|
448
+41%
|
470
+5%
|
|
| Equity | ||||||||||
| Common Stock |
16
|
16
|
16
|
44
|
44
|
44
|
44
|
117
|
117
|
|
| Retained Earnings |
52
|
89
|
140
|
230
|
255
|
376
|
486
|
471
|
550
|
|
| Additional Paid In Capital |
11
|
11
|
11
|
318
|
318
|
318
|
318
|
841
|
844
|
|
| Total Equity |
79
N/A
|
116
+48%
|
167
+44%
|
591
+254%
|
617
+4%
|
737
+20%
|
848
+15%
|
1 429
+69%
|
1 510
+6%
|
|
| Total Liabilities & Equity |
245
N/A
|
317
+29%
|
347
+10%
|
727
+110%
|
919
+26%
|
1 018
+11%
|
1 165
+14%
|
1 877
+61%
|
1 980
+6%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
16
|
16
|
16
|
44
|
44
|
44
|
44
|
117
|
117
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
